The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver DiseaseNa Li, Xiaoyu Hu, Liyuan Hao et al.|Journal of Inflammation Research|2024Cited by 61
The current status and future of PD-L1 in liver cancerLiyuan Hao, Xiaoyu Hu, Xinli Shi et al.|Frontiers in Immunology|2023Cited by 55
Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1Shenghao Li, Xinli Shi, Qingzhuo Cui et al.|Molecular and Cellular Biochemistry|2020Cited by 51
Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting <scp>YAP1</scp> expression to enhance <scp>anti‐PD</scp>‐1 efficacyQing Peng, Yiwei Liu, Liyuan Hao et al.|Phytotherapy Research|2022Cited by 33
Natural products target glycolysis in liver diseaseShenghao Li, Xiaoyu Hu, Liyuan Hao|Frontiers in Pharmacology|2023Cited by 22